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Background. The T allele of the G protein b3 subunit
(GNB3) C825T polymorphism has been associated with in-
creased signal transduction, increased activity of the kidney
Na+/H+ exchanger, and also with late-onset essential hyper-
tension. Hypertension is a strong independent risk factor for
progression in IgA nephropathy (IgAN).
Methods. We have studied this polymorphism in a regularly
followed cohort of 299 biopsy-proven incident cases of IgAN,
collected from 1989 to 1999 [208 males (70%)] and compared
the genotypes and alleles distributions to 303 local Caucasian
controls matched for the male predominance (214 males). The
technique used was a polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) with BseDI as
restriction enzyme and specific primers, followed by gel
electrophoresis.
Results. The TT, CT, and CC genotype frequencies were
13.7%, 45.8%, and 40.5% in IgAN, respectively, versus 7.6%,
47.2%, and 45.2% in controls, respectively (v 2 = 6.16; P = 0.05).
The excess of TT patients versus non-TT was significant in IgAN
versus controls (v 2 = 5.94; P = 0.015). The T allele frequency
was 0.366 in IgAN versus 0.312 in controls (v 2 = 3.97; P = 0.05).
This data indicated that this polymorphism had a significant but
mild influence on the occurrence/initiation of IgAN (RR = 1.81;
95% CI 1.07–3.07). In contrast, we could not demonstrate any
significant and sustained difference in the clinical presentation
and evolution of the homozygous TT patients compared to non-
TT patients (CC + CT) despite a mean and median follow-up
about 10 years. The progression to arterial hypertension or to
chronic renal failure or to end-stage renal failure (ESRF) was
not significantly different. In addition, multivariate Cox regres-
sion analysis excluded a significant independent role of C825T
polymorphism on progression.
Conclusion. The C825T GNB3 polymorphism had a mild in-
fluence on occurrence/initiation of IgAN, but played no signifi-
cant role in the progression of the disease.
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Primary IgA nephropathy (IgAN) is the most frequent
glomerulonephritis worldwide and represents between
the one third and one half of the glomerular diseases.
Its incidence ranges from 15 to 40 new cases per million
population [1].
The long-term prognosis is determined by the occur-
rence of chronic renal failure (CRF) (one half of the
patients after 20 years of evolution) and end-stage re-
nal failure (ESRF) (one fourth of the patients) [2, 3]. The
commonly accepted risk factors for progression of the dis-
ease are arterial hypertension, 24-hour proteinuria over
1 g, and severe pathologic lesions [4–6]. Arterial hyper-
tension is a major factor and usually precedes occurrence
of CRF [4].
In essential hypertension, studies have demonstrated
an enhanced signal transduction via G proteins with in-
creased activity of the Na+/H+ exchanger in lymphoblasts
and fibroblasts from affected patients [7, 8].
A novel polymorphism (C825T) in exon 10 of the gene
encoding the b3 subunit of the heterotrimeric G proteins
(GNB3) has been detected [9]. The T allele was associated
with the occurrence of a splice variant GNB3-s (encoding
Gb3-s) in which the nucleotides 498–620 of exon 9 were
deleted. This 123 bp deletion causes the loss of 41 amino
acids in the b3 subunit. This truncated splice is func-
tional and was associated with gain function, enhanced
Na+/H+ exchanger and hypertension [9]. This association
with late-onset hypertension was further confirmed in dif-
ferent populations [10–12]. Furthermore, several reports
have shown a strong association between obesity and this
825T allele; it was demonstrated that the frequency of T
allele was significantly increased in overweight and obese
individuals compared to those with normal weight [13–
15].
These two sets of data led us to study the C825T poly-
morphism of GNB3 in our cohort of IgAN. The goals
were (1) to determine the alleles (C, T) frequencies
and the genotypes distribution (CC, CT, TT) in patients
with IgAN compared to appropriate controls; and (2) to
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carefully study the genotype/phenotype correlation to de-
tect any influence on disease progression.
METHODS
The subjects
This is a case-control study for detection of associa-
tion(s).
The patients
We have studied 299 consecutive Caucasian patients
[208 males (69.6%) and 91 females] with the diagnosis
of biopsy-proven IgAN collected from 1989 to 1999 (in-
cident cases) and regularly followed in the nephrology
department. All these patients had no evidence of sec-
ondary causes such as liver cirrhosis, lupus nephritis, or
Henoch-Scho¨nlein Purpura.
This cohort of patients from Saint-Etienne area (IgAN
CO-STET) is prospectively followed and adequately
treated for arterial hypertension and/or proteinuria
>1 g/day. Most of the patients are receiving long-term
treatment with angiotensin-converting enzyme (ACE)
inhibitors and/or angiotensin II (Ang II) receptor an-
tagonists. At onset of the disease, 59 patients were al-
ready hypertensive either long before or diagnosed at
time of discovery. Fourteen patients presented also with
some degree of CRF diagnosed at time of discovery of the
disease. At time of diagnosis [first renal biopsy (RB1)],
the mean age was 40.2 years (SD = 14.9) for males and
40.2 years (SD = 14.6) for females. The mean and median
proteinuria (g/day) were 0.90 (SD = 1.27) and 0.45; the
mean and median serum creatinine (lmol/L) were 130.9
(SD = 134.2) and 91; 105 patients were hypertensive,
35.1% (blood pressure over 140/90 mm Hg at two differ-
ent occasions and thereafter treated). CRF was defined
according to the K/DOQI Clinical Practice Guidelines
for Chronic Kidney Diseases [16] as a glomerular filtra-
tion rate <60 mL/min × 1.73 m2 and calculated by the
Cockcroft-Gault equation. At RB1, 67 patients (22.4%)
had already some degree of CRF. In addition, 81 patients
with severe pathologic score and/or heavy proteinuria
were treated with high dose of steroids after diagnosis
and whenever indicated. Therefore, this is not the natu-
ral history of our cohort.
The controls
The control group was matched for gender to fit the
male predominance of IgAN and consisted of 303 lo-
cal Caucasian healthy volunteers: 214 males (70.6%) and
89 females. The mean and median body mass index for
these controls were 23.02 (2.88) and 23.18. The percent-
age of overweight controls (28%) was in accordance to
data concerning the French general population.
Each patient and control gave informed consent to this
genetic study.
Table 1. G protein b3 subunit 825C/T genotypes distribution and
allelic frequencies
Controls IgA nephropathy
Number (%) Number (%) Chi-squared P value
Genotypes
TT 23 (7.6) 41 (13.7)
CT 143 (47.2) 137 (45.8) 6.16 0.046
CC 137 (45.2) 121 (40.5)
Total 303 (100) 299 (100)
Alleles
T 189 (31.2) 219 (36.6) 3.97 0.046
C 417 (68.8) 379 (63.4)
Total 606 (100) 598 (100)
Clinical and pathologic data in IgAN patients
Clinical data. We collected for these patients at time of
the RB1 the following parameters: the amount of protein-
uria (g/24 hours), the presence of arterial hypertension,
the plasma creatinine (lmol/L), the presence of CRF as
already defined. In addition, we have collected height
(m), weight (kg) and calculated body mass index (kg/m2):
weight/height2. Overweight was defined as body mass in-
dex between 25 and 29.99 and obesity as body mass index
≥30 kg/m2.
Pathologic data at RB1. We used the global optical
score (GOS) ranging from 0 to 20, which is the sum of
glomerular (0 to 6), vascular (0 to 5), interstitial (0 to 5),
and tubular (0 to 4) indices [4]. The scoring was done
by our pathologist as a routine procedure, and without
knowledge of the clinical data. This parameter has al-
ready been shown to be an independent risk factor for
progression toward CRF [4].
Clinical progression. The major end point of the study
was the occurrence of CRF as already defined. The sec-
ondary end points were 24-hour proteinuria, hyperten-
sion, and ESRF.
Genotyping of G protein b3 subunit
825C/T polymorphism
For each patient, 25 mL of ethylenediaminetetraacetic
acid (EDTA) blood were obtained to isolate genomic
DNA, according to standard procedures. Genotyping
was performed by polymerase chain reaction (PCR),
followed by restriction fragment length polymorphism
(RFLP) [15]. PCR was performed with 250 ng of ge-
nomic DNA and 12.5 pmol of primers GP-1 (sense,
5-TGACCCACTTGCCACCCGTGC-3′) and GP-2 (an-
tisense, 5′-GCAGCAGCCAGGGCTGGC-3′) in a reac-
tion volume of 50 lL. Reaction conditions per cycle were
as follows: denaturation at 94◦C for 15 seconds, annealing
at 60◦C for 15 seconds, and elongation at 72◦C for 30 sec-
onds (35 cycles were performed). Reaction products were
digested with the restriction enzyme BseD1 (Fermentas
GmbH, St. Leon-Rot, Germany) and then separated on
3% agarose Nusieve gel, stained with ethidium bromide,
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Table 2. Correlations between G protein b3 subunit 825C/T genotypes and clinical phenotype in IgA nephropathy patients
Parameter Total CC CT TT P value
Number 299 121 137 41
Gender male/female 208/91 85/36 96/41 27/14 NS
Age at onset years, mean (SD) 34.5 (15.0) 33.7 (15.2) 35.6 (14.6) 33.2 (16.1) NS
At diagnosis (RB1)
GOS 1 7.09 (3.31) 7.45 (3.40) 6.97 (3.17) 6.44 (3.44) NS
Proteinuriaa g/day
Mean (SD) 0.90 (1.27) 1.06 (1.54) 0.84 (1.07) 0.66 (0.93) NS
Median 0.45 0.48 0.50 0.20 NS
Serum creatinine lmol/L
Mean (SD) 130.9 (134.2) 133.6 (133.4) 125.1 (115.5) 142.2 (188.4) NS
Median 91.0 91.0 94.0 88.0 0.03 (TT vs. CT)
Hypertension (%) 105 (35.1) 46 (38.0) 46 (33.6) 13 (31.7) NS
Chronic renal failure (%) 67 (22.4) 33 (27.3) 26 (19.0) 8 (19.5) NS
With ESRF (stage 5) (%) 10 (3.3) 4 (3.3) 3 (2.2) 3 (7.3) NS
Body mass indexb kg/m2, mean (SD) 24.7 (4.1) 24.5 (3.9) 24.7 (4.3) 24.8 (4.2) NS
Overweight/obesity (%) 119 (40.1) 46 (38.3) 56 (40.9) 17 (42.5) NS
At last follow-up
Time from onset months
Mean (SD) 139.5 (107.6) 133.2 (90.7) 151.0 (123.2) 119.8 (94.7) NS
Median 113.7 120.3 115.3 98.9 NS
Proteinuriaa g/day
Mean (SD) 0.35 (0.65) 0.39 (0.73) 0.35 (0.64) 0.27 (0.38) NS
Median 0.13 0.13 0.15 0.11 NS
Serum creatinine lmol/L
Mean (SD) 182.6 (225.6) 191.6 (234.2) 170.4 (205.5) 196.9 (264.7) NS
Median 95.0 96.0 97.0 89.0 0.05 (TT vs. CT)
Hypertension (%) 138 (46.2) 55 (45.5) 65 (47.4) 18 (43.9) NS
New patients/exposed (%) 33/194 (17.0) 9/75 (12.0) 19/91 (20.4) 5/28 (17.9) NS
Chronic renal failure (%) 82 (27.4) 35 (28.9) 39 (28.5) 8 (19.5) NS
With ESRF (stage 5) (%) 35 (11.7) 16 (13.2) 13 (9.5) 6 (14.6) NS
New CRF patients/exposed (%) 15/232 (6.5) 2/88 (2.3) 13/111 (11.7) 0/33 (0.0) 0.007
New ESRF patients/exposed (%) 25/289 (8.7) 12/117 (10.3) 10/134 (7.5) 3/38 (7.9) NS
Abbreviations are: RB1, first renal biopsy; GOS 1, global optical score at RB1; ESRF, end-stage renal failure.
aFor proteinuria, we excluded patients with ESRF (giving 289 patients at RB1 and 264 at last follow-up).
bFor body mass index, we had information on only 297 patients.
and visualized under ultraviolet illumination. The undi-
gested PCR product (TT genotype) gave only one band of
268 bp. The completely digested PCR product (CC geno-
type) generated two bands of 152 bp and 116 bp, re-
spectively. Heterozygotes (CT genotype) produced three
bands of 268 bp, 152 bp, and 116 bp.
Statistical analysis
Comparison between patients and controls. Analy-
ses were done with Statview 5.0 (Abacus Concepts, Inc,
Berkeley, CA, USA). Genotypes distributions, alleles fre-
quencies among controls and IgAN were compared using
standard chi-squared tests.
The power of this study for allelic comparison was at
least 90% based on the total of alleles (individuals × 2), a
risk a = 0.05, a risk b = 0.10 and permitted the detection
of a 10% difference.
Clinicopathologic parameters among patients with dif-
ferent genotypes. The qualitative variables such as class
of proteinuria, class of body mass index, hypertension,
CRF, and ESRF were compared using chi-squared con-
tingency table. The quantitative variables such as pro-
teinuria (g/24 hours), body mass index, GOS, and plasma
creatinine were compared using either t test or nonpara-
metric test (Mann-Whitney U test) when applicable.
Survival curves without CRF were analyzed according
to Kaplan-Meier method and compared using the log-
rank test. The event was CRF as already defined, time
zero was the onset/discovery of the disease, and the final
date was either the date of the event or the date of the
last follow-up (censored patients). In case of a significant
difference, the Cox multivariate analysis was performed
using all significant covariates or at least the ones already
known to influence the prognosis: hypertension, GOS,
24-hour proteinuria, body mass index, plus gender.
RESULTS
G protein b3 subunit 825C/T genotypes distribution
and allelic frequencies
There was a small statistical difference in the genotypes
(CC, CT, TT) and allelic (C, T) distributions between
patients and controls. The T allele frequency is slightly
increased: 36.6% versus 31.2%; v 2 = 6.16; P = 0.046
(Table 1).
After grouping either CC + CT genotypes (C allele)
or TT + CT genotypes (T allele), we could confirm a
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Table 3. Correlations between G protein b3 subunit 825C/T genotypes and clinicopathologic data in IgA patients
Parameter C allele (CT + CC) TT P value
Number 258 41
Gender male/female 181/77 27/14 NS
Age at onset years, mean (SD) 34.7 (14.9) 33.2 (16.1) NS
At diagnosis (RB1)
GOS 1 mean (SD) 7.20 (3.29) 6.44 (3.44) NS
Proteinuriaa g/day
Mean (SD) 0.94 (1.31) 0.66 (0.93) NS
Median 0.49 0.20 NS (0.10)
Serum creatinine lmol/L
Mean (SD) 129.1 (124.1) 142.2 (188.4) NS
Median 93.0 88.0 0.03
Hypertension (%) 92 (35.7) 13 (31.7) NS
Chronic renal failure (%) 59 (22.9) 8 (19.5) NS
With ESRF (stage 5) (%) 7 (2.7) 3 (7.3) NS
Body mass indexb kg/m2, mean (SD) 24.6 (4.1) 24.8 (42) NS
Overweight/obesity (%) 102 (39.7) 17 (42.5) NS
At last follow-up
Time from onset months
Mean (SD) 142.8 (109.5) 119.8 (94.7) NS
Median 117.1 98.9 NS
Proteinuriaa g/day
Mean (SD) 0.37 (0.68) 0.27 (0.38) NS
Median 0.13 0.11 NS
Creatininemia lmol/L
Mean (SD) 182.4 (222.5) 196.9 (264.7) NS
Median 96.5 89.0 0.045
Hypertension (%) 120 (46.5) 18 (43.9) NS
New patients/exposed (%) 28/166 (16.9) 5/28 (17.9) NS
Chronic renal failure (%) 74 (28.7) 8 (19.5) NS
With ESRF (stage 5) (%) 29 (11.2) 6 (14.6) NS
New CRF patients/exposed (%) 15/199 (7.5) 0/33 (0.0) NS (0.10)
New ESRF patients/exposed (%) 22/251 (8.8) 3/38 (7.9) NS
Abbreviations are: RB1, first renal biopsy; GOS 1, global optical score at RB1; ESRF, end-stage renal failure.
aFor proteinuria, we excluded patients already with ESRF (giving 289 patients at RB1 and 264 at last follow-up).
bFor body mass index, we had information on only 297 patients.
Table 4. Survival without chronic renal failure (CRF) glomerular filtration rate (GFR) (<60 mL/min/1.73 m2)
Time 0 1 year 5 years 10 years 15 years 20 years
Total At risk 299 273 215 118 60 30
Probability 1.00 0.92 0.86 0.77 0.70 0.65
TT At risk 41 37 30 15 8 4
Probability 1.00 0.93 0.88 0.78 0.78 0.78
C allele At risk 258 236 185 103 53 26
Probability 1.00 0.92 0.86 0.77 0.70 0.64
TT versus C allele by Log-rank test, P = NS (0.06).
significant excess of TT individuals in patients versus con-
trols: 13.7% versus 7.6%; v 2 = 5.94; P = 0.015; odds ra-
tio (OR) = 1.93 (95% CI 1.14–3.28); and relative risk
(RR) = 1.81 (95% CI 1.07–3.07).
This data indicates that G protein b3 subunit polymor-
phism does play a significant but moderate role in the
initiation/occurrence of IgAN.
Genotype to phenotype correlation:
Clinicopathologic data
The characteristics of the subgroups of patients accord-
ing to G protein b3 subunit genotype (CC, CT, and TT)
are given in Table 2. Despite the fact that there was no
significant difference among the subgroups, the TT sub-
group (N = 41) presented with a slightly milder disease at
diagnosis (RB1): lower GOS, lower proteinuria, slightly
less hypertension, and about the same findings at last
follow-up.
Therefore, we directly compared TT patients and non-
TT patients (CC + CT) (e.g., patients with C allele) in
Table 3. We could demonstrate a lower median creatinine
both at RB1 (P = 0.03) and at last follow-up (P = 0.045)
in the TT subgroup. There was also a tendency for lower
24-hour proteinuria at RB1 (P = 0.10) and less CRF at
last follow-up.
In addition, the number of new patients with CRF since
renal biopsy (diagnosis) was 0% for TT (0/33) versus
11.7% for CT (13/111) and 2.3% for CC (2/88), indicat-
ing less progression. Nevertheless, the total number of
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Fig. 1. Survival without chronic renal fail-
ure (CRF) defined as Cockroft<60 mL/min/
1.73 m2 and according to the C825T polymor-
phism of GNB3 gene.
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Fig. 2. Survival without hypertension and ac-
cording to the C825T polymorphism of GNB3
gene.
patients progressing to ESRF was not different among
the subgroups.
Survival data without CRF in these patients is given
in Table 4 and Figure 1. Survival in the TT subgroup
was similar to the C allele subgroup during the first
10 years but remained stable thereafter with divergent
curves (log-rank test P = 0.06). Cox multivariate analysis
with classical risk factors as covariates confirmed that this
C825T polymorphism was not an independent factor for
progression.
There was no significant influence of GNB3 polymor-
phism on secondary end points such as hypertension and
ESRF. The survival data without hypertension (Fig. 2)
or without ESRF (Fig. 3) showed no difference among
genotypes.
Validity of the data
Expected genotype frequencies from the observed al-
lele frequencies did not deviate from Hardy-Weinberg
equilibrium: T allele frequency = 0.366 (219/598); C allele
frequency = 0.634 (379/598); TT genotype = [0.366]2 ×
299 = 40; CC genotype = [0.634]2 × 299 = 120; CT geno-
type = 2 [0.366 × 0.634] × 299 = 139. The genotypes
distribution observed were 41, 121, and 137, respectively.
There was no statistical difference between theoretical
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Fig. 3. Survival without end-stage renal fail-
ure (ESRF) defined as Cockroft stage 5 (e.g.,
<15 mL/min) and according to the C825T
polymorphism of GNB3 gene. Note that all
patients were on dialysis but one.
and observed genotypes distributions (v 2 = 0.031; P =
NS).
DISCUSSION
In the general normotensive Western population, the
825T allele frequency was calculated 0.25 (N = 427) [9]
and 0.28 (N = 1000) [11] in Germany, 0.25 in Australia
(N = 189) [10], 0.30 in Northern Ireland (N = 163) [17],
and 0.31 in France (N = 470) [14]. In our study, we have
found the same T allele frequency 0.312 in 303 local con-
trols, thus validating our technique. By contrast, the fre-
quency rose to 0.50 in the Japanese population [12] and
reached 0.82 in black Africans and black Americans [13,
14].
As already mentioned, the T allele is associated with
late-onset essential hypertension in virtually all studies
[9–12, 18], except one [17], where the selection of patients
might have not been optimal. In addition, the T allele was
also associated with subgroups of arterial hypertension:
diastolic hypertension and low renin [19]; and hyperten-
sion with left ventricular hypertrophy [20]. These differ-
ent works are association studies which do not imply a
direct causative role. In our study, we could not demon-
strate any difference regarding hypertension either at on-
set of the disease (59 patients) or at time of diagnosis
(105 patients) or at last follow-up (138 patients) and ac-
cording to the different genotypes.
In fact, the relation between T allele and hyperten-
sion is not direct, but overweight and obesity appear as
(one of) the missing link(s) [15]. The frequency of T allele
was significantly increased with obesity: 0.238 in hyper-
tensive patients with normal body mass index; 0.314 in
overweight and 0.40 in obese patients. This finding was
found in worldwide populations [13, 14]. In our study, the
T allele frequency was 0.378 in overweight/obese patients
(N = 119) compared to 0.357 in patients with normal body
mass index (N = 178; P = NS).
In a previous study on IgAN [21], we have demon-
strated that overweight/obesity was an independent risk
factor reducing both the hypertension-free and the CRF-
free survivals. For this reason, we have included abso-
lute body mass index and dichotomous body mass index
(normal versus overweight/obesity) in this study, but we
could not isolate C825T polymorphism as an independent
association.
As far as we know, this is the first study on the influ-
ence of GNB3 gene polymorphism in IgAN. However,
two studies have been published in other renal diseases.
The first from Blu¨thner et al [22] compared this C825T
polymorphism in older (>50 years) controls and in two
subgroups of older (>60 years at start) dialyzed patients:
one with type 2 diabetic nephropathy and the other with
nondiabetic nephropathies. The T allele frequency was
0.29 in 357 controls versus 0.23 in 125 dialyzed nondi-
abetic nephropathies versus 0.36 in type 2 diabetes on
dialysis and reached high significance. The second paper
from Gumprecht et al [23] has studied, by transmission
disequilibrium test, and in 247 familial trios of end-stage
renal disease (ESRD), the association between C825T
polymorphism and ESRD phenotype; the result was
negative.
In our study, we have found a significant increase (P =
0.046) of T allele frequency: 0.366 in patients versus 0.312
in controls, with a clear excess of homozygous TT patients
(P = 0.014). Finally, these TT patients presented with no
significant and sustained difference as compared to pa-
tients with the C allele (CC + CT). Furthermore, Cox
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regression was done on CRF-free survival, including
GOS, hypertension, 24-hour proteinuria (g/day), body
mass index (all at RB1), age at onset of the disease
(years), and C825T polymorphism as covariates. The re-
sults excluded an independent role for this polymorphism
and quantitative proteinuria, but confirmed GOS, age at
onset, absence of hypertension, absence of proteinuria
(<0.30 g/24 hours), and body mass index as significant
and independent risk factors.
IgAN is mainly due to an abnormal immune response,
characterized by increased synthesis of deglycosylated
IgA1 (loss of terminal galactose in the hinge region).
In addition, T-helper lymphocytes play a critical role
at the mucosal effector site in this disease [24]. Recently,
the G protein b3 subunit 825T allele has been shown
to enhance both the T-cell–specific response [25] and
chemotaxis of human neutrophils in response to different
stimuli [26]. So, we can speculate than individuals with TT
genotype may develop after trigger antigens exposure, in-
adequately enhanced immune response leading to renal
(mostly mesangial) inflammation, and lesions with the
characteristics of IgAN.
There is currently a debate on genetic associations with
complex diseases [27–29]. Obviously, IgAN presents with
complex outcomes: no CRF over decades; rapid progres-
sion to CRF (for instance in case of crescents); and slow
progression to CRF. Our cohort included all incident con-
secutive cases during the period 1989 to 1999, with very
few lost of follow-up (<10%) and should have included
these various outcomes. The Kaplan-Meier survival anal-
ysis takes in account the time as variable. Our cohort was
obviously not small but of medium size and the mean du-
ration of the disease was more than 10 years (mean =
140 months; median = 114 months). Hence, our method-
ology seemed correct and this C825T polymorphism had
no significant influence on progression of the disease. A
larger study remains still warranted.
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